Advice

in the absence of a submission from the holder of the marketing authorisation:

blinatumomab (Blincyto®) is not recommended for use within NHSScotland.

Indication under review: As monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).

Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice619KB (PDF)

Download

Medicine details

Medicine name:
blinatumomab (Blincyto)
SMC ID:
SMC2468
Indication:

As monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.

Pharmaceutical company
Amgen Ltd
Submission type
Non submission
Status
Not recommended
Date advice published
07 March 2022
Additional notes

SMC advice 1145/16 for adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia remains valid.